Macro :
- Ex-Goldman, Morgan Stanley Execs Join Crypto Unicorn Amber
Keep an eye on :
- AXFO SS : Axfood-Bergendahls Deal Cleared by Swedish Regulator
- BSLN SW : Basilea Derazantinib Phase 2 Study FIDES-01 ‘Very Encouraging’
After Hours Summary: ABCL jumps +21.1% as FDA expands EUA for COVID treatment; USNA -2.8% heads lower on guidance; X -1.6% ticks lower on guidance and development on new steel plantAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: EIX +0.1% (establishes in-line 2021 EPS guidance following favorable GRC final decision)
Companies trading higher in after hours in reaction to news: ABCL +21.1% (FDA expands EUA for bamlanivimab 700 mg and etesevimab 1400 mg to include post-exposure prophylaxis to prevent SARS-CoV-2 infection or symptomatic COVID-19), FANG +4.9% (approves up to $2.0 bln in new repurchase program), ZUMZ +3.3% (approves $150 mln stock repurchase authorization), NEXA +1.1% (names new CEO), CARR +0.8% (to acquire BrokerBay), IGT +0.8% (wins contract from the Connecticut Lottery), ECOM +0.7% (provides long-term financial targets; also $25 mln share repurchase program), WPC +0.6% (increases dividend), ALGN +0.2% (announces exclusive supply and distribution agreement with Ultradent)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: USNA -2.8% (guides Q3 revs below single est, lowers FY21 guidance; increases share repurchase program)
Companies trading lower in after hours in reaction to news: GRTS -5.1% (announces $55 mln private placement financing), X -1.6% (announces exploratory site selection process to build new $3 bln mini mill in the US; also guides EBITDA slightly above consensus), BLDP -0.9% (announces launch of the FCmove-HD+), SKT -0.1% (increases dividend), NOW -0.1% (Chief Accounting Officer stepping down), GLT -0.1% (will increase prices for all composite fibers products by 12%)
Gapping down
Select Macau gaming names showing early weakness:
- MLCO -8.4%, WYNN -5.6%, LVS -4.5%, MGM -1.5%
Other news:
- KAVL -37.9% (reports Q3 results; notes impact of FDA's PMTA process in discussing its decline in revenues, updates guidance for FY21)
- CDXC -21.7% (to defend IP portfolio; plans to appeal patent infringement lawsuit)
- TBPH -19.8% (reports Phase 3 study of Ampreloxetine did not meet the primary endpoint; takes strategic actions to focus on respiratory disease portfolio)
- AVTX -17.6% (prices offering of 12.5 mln shares of common stock at $2.20 per share)
- BBIO -14.2% (receives Fast Track Designation from FDA for investigational therapy for the treatment of Limb-girdle Muscular Dystrophy Type 2i)
- HUT -11.6% (stock offering)
- YUMC -4% (provides business update: Delta variant significantly impacted restaurant industry)
- PMTS -2.1% (files for $150 mln stock offering; also files for offering by selling shareholders)
- LYV -2% (prices offering of 5,239,259 shares of common stock at $86.90 per share)
- ASO -2% (prices secondary offering by affiliates of KKR of 18,645,602 shares of common stock at $44.75 per share)
Analyst comments:
- IART -0.9% (downgraded to Neutral from Buy at BTIG Research)
Gapping up
In reaction to earnings/guidance:
- IRNT +10%, JKS +1.1%, SKIL +1%
Other news:
- BPTS +10.7% (reports second interim analysis efficacy results in the promising zone allowing continuation of Phase 2/3 COVA Study)
- HOOK +5.6% (entered into a clinical collaboration and supply agreement with Merck & Co. (MRK))
- SAGE +5.5% (receives Fast Track Designation for SAGE-718)
- OPGN +4.7% (clinical data from an investigator-initiated and driven prospective randomized controlled multicenter study)
- BGNE +3.3% (BRUKINSA (zanubrutinib) receives accelerated approval from FDA for treatment of marginal zone lymphoma)
- OBSV +3% (submits NDA to FDA for Linzagolix)
- AFG +2.7% (declares a special dividend of $4.00/sh)
- JAMF +2.2% (prices $325.0 mln of Convertible Senior Notes due 2026)
- MRCY +2.1% (successfully demonstrates Sensor Open Systems Architecture aligned sensor processing platform at US Army)
- REGN +2% (awarded $2.9 bln Army contract; also receives US Gov't agreement to purchase 1.4 mln additional doses of REGEN-COV)
- YOU +1.9% (announces strategic partnership with Tappit)
- IDEX +1.9% (increases stake in Energica Motor Company)
- FTCI +1.7% (CEO to step down, replacement named)
- MSFT +1.2% (raises dividend by 11%; approves new $60 bln share repurchase)
Analyst comments:
- SRPT +2.8% (upgraded to Buy from Neutral at Guggenheim)
- KNX +2.4% (upgraded to Outperform from Market Perform at Cowen)
- SNDR +2.2% (upgraded to Outperform from Market Perform at Cowen)
- WERN +1.7% (upgraded to Outperform from Market Perform at Cowen)
Early premarket gappers
- Gapping up:
- OBSV +6.3%, BPTS +6.2%, VICR +4.8%, SKIL +4.5%, IRNT +4.2%, TRTX +3.5%, JAMF +2.2%, JKS +2.2%, MRCY +2.1%, YOU +1.9%, IDEX +1.9%, FTCI +1.7%, REGN +1.5%, LAW +1.4%, MSFT +1.3%, ADP +1.1%, HIG +0.8%
- Gapping down:
- KAVL -29%, TBPH -26.7%, AVTX -14.5%, HUT -11.2%, YUMC -4.8%, LYV -3.3%, VCYT -1%, PMTS -0.9%, BRP -0.9%, AGIL -0.5%